Trial Profile
POLEM:Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Exonuclease Domain Mutant Colon Cancer: A Phase 3 Randomised Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; Avelumab (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms POLEM
- 05 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 12 Jul 2021 Planned End Date changed from 1 Nov 2021 to 5 Jan 2022.
- 09 Mar 2021 Planned End Date changed from 1 Jul 2028 to 1 Nov 2021.